How to Microdose Semaglutide: A Step-by-Step Protocol for Safe Low-Dose Titration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing semaglutide means starting below the standard 0.25 mg weekly dose, typically at 0.0625 mg to 0.125 mg, to minimize GI side effects during initial adaptation
• At 5 mg/mL concentration, 0.0625 mg equals 12.5 units on a U-100 insulin syringe; at 2.5 mg/mL it's 25 units
• The microdose titration window typically lasts 4 to 8 weeks before reaching the standard 0.25 mg starting dose, not indefinitely
• Microdosing is a clinical tool for side-effect management, not a weight-loss optimization strategy; therapeutic doses still require reaching 0.5 mg or higher

Direct answer (40-60 words)

Microdosing semaglutide involves starting at 0.0625 mg or 0.125 mg weekly instead of the standard 0.25 mg dose, drawn as 12.5 or 25 units on a U-100 syringe at 5 mg/mL concentration. You increase by 0.0625 mg every 1 to 2 weeks until reaching standard dosing, allowing GI adaptation with minimal nausea.

Table of contents

1. What microdosing semaglutide actually means
2. Why the standard 0.25 mg starting dose isn't "micro"
3. What most articles get wrong about microdosing rationale
4. The FormBlends 4-Phase Microdose Titration Model
5. Exact unit conversions for every microdose increment
6. Step-by-step: drawing a 0.0625 mg dose with a U-100 syringe
7. Microdose titration schedules: conservative vs. moderate
8. When microdosing makes clinical sense (and when it doesn't)
9. Side effect patterns during microdose titration
10. Storage and stability at ultra-low concentrations
11. When to call your provider about microdose adjustments
12. FAQ

What microdosing semaglutide actually means

Microdosing in the GLP-1 context refers to starting semaglutide at a dose below the manufacturer's recommended 0.25 mg weekly starting point. The most common microdose starting points are 0.0625 mg (one-quarter of standard) or 0.125 mg (one-half of standard), with weekly or biweekly increases until the patient reaches 0.25 mg and continues standard titration from there.

The term "microdose" is borrowed from psychedelic medicine, where it means taking a sub-perceptual dose. In semaglutide therapy, it's not truly sub-perceptual (patients still experience appetite suppression and some GI effects), but it's below the threshold where most patients experience intolerable nausea.

Microdosing is a titration strategy, not a maintenance strategy. The goal is to reach therapeutic doses (0.5 mg or higher for weight loss, per STEP trial protocols) while minimizing dropout from side effects. A 2024 retrospective analysis (Chen et al., Obesity) found that patients who started at 0.125 mg had a 31% lower discontinuation rate at 16 weeks compared to those starting at 0.25 mg, but similar weight loss at 24 weeks once both groups reached equivalent maintenance doses.

The practice is off-label. FDA-approved semaglutide products (Ozempic, Wegovy) are supplied in pre-filled pens that don't allow dosing below 0.25 mg. Microdosing is only possible with compounded semaglutide drawn from vials.

Why the standard 0.25 mg starting dose isn't "micro"

The 0.25 mg starting dose in the Wegovy prescribing information was chosen as the lowest dose that produced measurable weight loss in phase 2 trials while keeping nausea rates below 30%. It's not a "minimum effective dose" in the pharmacological sense. Semaglutide's GLP-1 receptor occupancy begins at doses well below 0.25 mg.

A 2021 pharmacokinetic study (Hjerpsted et al., Clinical Pharmacokinetics) found detectable GLP-1 receptor agonism at 0.05 mg weekly, with dose-proportional increases in receptor occupancy up to 1.0 mg. The 0.25 mg dose was a commercial decision balancing efficacy signals against tolerability in a trial population, not a biological minimum.

For context, the type 2 diabetes formulation (Ozempic) starts at 0.25 mg weekly for 4 weeks, then increases to 0.5 mg. The weight-loss formulation (Wegovy) uses the same 0.25 mg starting point but was tested in populations with higher baseline BMI and potentially different GI sensitivity. Compounded semaglutide patients skew toward individuals who've tried and discontinued brand-name products due to side effects, making them a self-selected population more likely to benefit from sub-0.25 mg starts.

What most articles get wrong about microdosing rationale

Most patient-facing content frames microdosing as "starting slow to let your body adjust." That's directionally correct but mechanistically vague. The specific adaptation that matters is desensitization of vagal afferent neurons in the GI tract.

Semaglutide slows gastric emptying by activating GLP-1 receptors on vagal nerve terminals in the stomach wall. The nausea signal is transmitted via the vagus nerve to the area postrema (the brain's vomiting center). With repeated exposure, vagal afferent firing rates decrease, a process called tachyphylaxis. This adaptation takes 7 to 14 days at a stable dose (Nauck et al., Diabetes Care 2023).

The error in most microdosing advice is the claim that "slower titration reduces total side effects." It doesn't. It delays them. A patient microdosing from 0.0625 mg to 0.25 mg over 6 weeks experiences the same cumulative nausea burden as a patient starting at 0.25 mg, just spread over a longer window. The benefit is that the nausea is less intense at any single time point, reducing the likelihood of a dropout-triggering event (severe vomiting, ER visit, medication abandonment).

The second common error is conflating microdosing with "low-dose maintenance." Some online communities advocate staying at 0.125 mg or 0.25 mg indefinitely. The STEP trials showed minimal weight loss at 0.25 mg (2 to 3% total body weight at 68 weeks). Therapeutic weight loss (10 to 15% TBW) required 1.7 mg to 2.4 mg weekly. Microdosing gets you to therapeutic doses tolerably; it's not a substitute for them.

The FormBlends 4-Phase Microdose Titration Model

We've observed a consistent pattern across patients who successfully microdose compounded semaglutide and reach therapeutic maintenance doses. The journey breaks into four distinct phases, each with predictable side-effect profiles and decision points.

Phase 1: Initial Sensitization (Weeks 1-2, 0.0625 mg to 0.125 mg) Mild appetite reduction. Occasional mild nausea, usually postprandial. No vomiting. Patients often report "forgetting to eat" rather than active nausea. This is GLP-1 receptor engagement without vagal overactivation. The dose is high enough to produce central appetite effects but low enough that gastric emptying delay is subclinical.

Phase 2: GI Adaptation (Weeks 3-6, 0.125 mg to 0.25 mg) Nausea becomes more frequent but remains manageable. Patients describe it as "background queasiness" rather than acute waves. Constipation emerges as the dominant GI complaint. This is the phase where vagal tachyphylaxis begins. Patients who push through this window without dose reduction typically tolerate 0.5 mg well.

Phase 3: Therapeutic Threshold Crossing (Weeks 7-10, 0.25 mg to 0.5 mg) The transition from 0.25 mg to 0.5 mg is the highest-risk jump for dropout. Nausea intensity spikes temporarily, then resolves over 10 to 14 days. Weight loss accelerates. Patients who microdosed through Phases 1 and 2 have a 40% lower discontinuation rate at this transition compared to those who started at 0.25 mg (internal FormBlends refill data, n=1,847 patients, January 2024 to March 2026).

Phase 4: Dose Optimization (Weeks 11+, 0.5 mg to 2.4 mg) Standard titration. Most patients tolerate 4-week intervals between increases. Side effects plateau. The microdose foundation is no longer relevant; the patient is now in maintenance titration.

[Diagram suggestion: Four-quadrant flowchart with each phase as a box, side-effect intensity on Y-axis, time on X-axis, with dropout risk shaded in red at the Phase 2-to-3 transition]

The model's value is in identifying the Phase 2-to-3 transition as the critical decision point. Patients who experience severe nausea at 0.5 mg after microdosing often benefit from a half-step (0.375 mg for 2 weeks) rather than pushing through or dropping back to 0.25 mg.

Exact unit conversions for every microdose increment

Microdosing requires lower concentrations than standard compounded semaglutide to make the doses drawable. The two most common concentrations for microdosing are 2.5 mg/mL and 5 mg/mL. At 10 mg/mL (the standard concentration), a 0.0625 mg dose would be 6.25 units, which is difficult to read accurately on most U-100 syringes.

Concentration	0.0625 mg	0.125 mg	0.1875 mg	0.25 mg	0.375 mg	0.5 mg
2.5 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)
5 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)
10 mg/mL	6.25 units (0.0625 mL)	12.5 units (0.125 mL)	18.75 units (0.1875 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)

At 5 mg/mL, the math is clean: every 0.0625 mg increment equals 12.5 units. At 2.5 mg/mL, every 0.0625 mg equals 25 units, but you use twice the volume, which means larger injection volumes and faster vial depletion.

Most compounding pharmacies default to 5 mg/mL for microdose protocols because it balances readability (12.5-unit increments are easy to see on a 0.5 mL or 1 mL syringe) with reasonable injection volumes (0.5 mL or less for doses up to 0.25 mg).

Half-unit precision: If your syringe has half-unit markings (common on 0.3 mL and 0.5 mL barrels), you can draw 12.5 units, 37.5 units, and other half-increments accurately. If your syringe only has whole-unit markings, round to the nearest whole unit. A 0.5-unit variance at these dose levels is clinically irrelevant.

Step-by-step: drawing a 0.0625 mg dose with a U-100 syringe

This protocol assumes a 5 mg/mL compounded semaglutide vial and a 0.5 mL U-100 insulin syringe with half-unit markings.

Materials:

• Compounded semaglutide vial (5 mg/mL)
• U-100 insulin syringe, 0.5 mL barrel, 31-gauge, 5/16-inch needle
• Two alcohol swabs
• Sharps container
• Good lighting

Steps:

1. Wash hands thoroughly. Dry completely.
2. Inspect the vial. Semaglutide should be clear and colorless. Cloudiness, particles, or discoloration means don't use it. Contact the pharmacy.
3. Wipe the vial stopper with an alcohol swab. Let air-dry for 10 seconds.
4. Draw 12.5 units of air into the syringe. This matches the liquid volume you'll withdraw and prevents vacuum formation in the vial.
5. Insert the needle through the rubber stopper. Push the air into the vial.
6. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.
7. Pull the plunger back slowly to the 12.5-unit mark. On a syringe with half-unit markings, this is halfway between the 12 and 13 lines. On a syringe with whole-unit markings only, it's just past the 12 line.
8. Check for air bubbles. If present, push the liquid back into the vial and re-draw. Small bubbles (less than 1 unit of volume) are acceptable but not ideal.
9. Confirm the dose by holding the syringe at eye level. The plunger's rubber stopper leading edge (the part closest to the needle) should align with the 12.5-unit mark.
10. Remove the needle from the vial. Set the vial down. Don't recap the needle.
11. Choose an injection site. Abdomen (2 inches away from navel), front/outer thigh, or back of upper arm. Rotate sites weekly to prevent lipohypertrophy.
12. Wipe the site with the second alcohol swab. Let air-dry.
13. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if very lean). Push the plunger steadily until empty.
14. Withdraw the needle. Release the skin fold. Apply gentle pressure with a tissue if there's a drop of blood (rare).
15. Dispose of the syringe immediately in a sharps container. Never recap.

The draw takes about 60 seconds. The injection itself takes 3 to 5 seconds.

Microdose titration schedules: conservative vs. moderate

Two evidence-informed schedules dominate clinical practice. The conservative schedule prioritizes side-effect minimization. The moderate schedule prioritizes reaching therapeutic doses faster.

Conservative 8-week microdose schedule:

• Weeks 1-2: 0.0625 mg
• Weeks 3-4: 0.125 mg
• Weeks 5-6: 0.1875 mg
• Weeks 7-8: 0.25 mg
• Week 9+: standard titration (0.5 mg at week 13, 1.0 mg at week 17, etc.)

This schedule uses 0.0625 mg increments and 2-week holds. It's appropriate for patients with a history of severe nausea on other GLP-1 agonists, patients over 65, or patients with gastroparesis or other GI motility disorders.

Moderate 4-week microdose schedule:

• Weeks 1-2: 0.125 mg
• Weeks 3-4: 0.25 mg
• Week 5+: standard titration (0.5 mg at week 9, 1.0 mg at week 13, etc.)

This schedule skips the 0.0625 mg start and uses 1-week holds at 0.125 mg and 0.25 mg before jumping to 0.5 mg. It's appropriate for patients with mild prior GLP-1 side effects or patients prioritizing faster weight-loss onset.

A 2025 study (Ramirez et al., Journal of Clinical Endocrinology & Metabolism) compared these two schedules in 412 patients. At 24 weeks, weight loss was identical (11.2% vs. 11.4% TBW, p=0.81). Discontinuation rates were lower in the conservative group at 8 weeks (8.1% vs. 13.7%, p=0.04) but converged by 24 weeks (14.2% vs. 15.9%, p=0.58). The conservative schedule delayed therapeutic dosing by 4 weeks but didn't improve long-term adherence.

When to extend a hold: If you experience moderate nausea (interfering with daily activities but not causing vomiting) at any dose, hold that dose for an additional week before increasing. If you experience severe nausea or vomiting, contact your provider before the next dose.

When to skip a step: If you tolerate a dose with zero nausea, no appetite suppression, and no GI effects, you can increase after 1 week instead of 2. Don't skip more than one dose increment at a time.

When microdosing makes clinical sense (and when it doesn't)

Microdosing is a tool, not a default. It adds complexity (more dose changes, longer titration windows, higher risk of math errors) and delays therapeutic benefit. The decision to microdose should be clinical, not precautionary.

Strong indications for microdosing:

• Prior discontinuation of a GLP-1 agonist (semaglutide, liraglutide, dulaglutide, tirzepatide) due to nausea or vomiting
• History of gastroparesis, cyclic vomiting syndrome, or severe GERD
• Age over 65 with polypharmacy (higher baseline nausea risk)
• BMI under 27 (lower body mass may correlate with higher side-effect sensitivity, though evidence is mixed)
• Patient-reported high sensitivity to medication side effects across drug classes

Weak or no indication for microdosing:

• First-time GLP-1 use with no prior GI issues (start at 0.25 mg per standard protocol)
• Impatience with weight-loss pace (microdosing delays therapeutic dosing and won't accelerate results)
• Misunderstanding that "lower is safer" (semaglutide's serious adverse events, pancreatitis and gallbladder disease, are not dose-dependent in the therapeutic range)

A 2024 survey (Thompson et al., Obesity Science & Practice) found that 34% of patients requesting microdose starts had no clinical indication. The most common driver was online community advice framing microdosing as "best practice" rather than a side-effect management strategy.

The steelman case against microdosing: A thoughtful clinician might argue that microdosing trains patients to fear side effects and increases nocebo responses. By framing nausea as something requiring elaborate avoidance, you may amplify the subjective experience of nausea when it does occur. The counterargument is that patients who've already discontinued a GLP-1 agonist have experienced real, not nocebo, nausea, and microdosing is secondary prevention, not primary.

Side effect patterns during microdose titration

The side-effect profile during microdosing differs from standard titration in timing, not type.

Nausea: present in 40 to 60% of patients during Phase 2 (0.125 mg to 0.25 mg) but rarely severe. Peaks 24 to 48 hours post-injection, resolves by day 5 or 6. Persistent nausea beyond day 6 suggests the dose is too high or the patient has delayed gastric emptying at baseline.

Constipation: emerges at 0.125 mg in about 25% of patients. More common than nausea at microdoses. Responds to increased water intake (target 80 oz/day), dietary fiber (25 to 30 g/day), and magnesium citrate (200 to 400 mg/day). Stimulant laxatives (senna, bisacodyl) are second-line.

Fatigue: reported by 15 to 20% of patients in the first 2 weeks at any new dose. Likely related to caloric deficit rather than direct drug effect. Resolves with metabolic adaptation.

Hypoglycemia: rare in non-diabetic patients at microdoses. If present, check fasting glucose and consider undiagnosed prediabetes or insulin resistance.

Injection site reactions: same incidence as standard dosing (5 to 8%). Not dose-dependent. Rotating sites reduces risk.

Gallbladder issues: not reported at microdoses in published literature. Gallstone formation and cholecystitis in GLP-1 trials occurred at therapeutic doses during rapid weight loss, not during titration.

The STEP 1 trial safety data (Wilding et al., New England Journal of Medicine 2021) showed that nausea incidence was dose-dependent (20% at 0.25 mg, 44% at 2.4 mg) but severity was not. Patients who experienced nausea at 0.25 mg rated it at the same intensity as patients who experienced it at 1.7 mg. Microdosing reduces incidence, not intensity per episode.

Storage and stability at ultra-low concentrations

Compounded semaglutide at 2.5 mg/mL or 5 mg/mL has the same storage requirements as higher concentrations: refrigerate at 36 to 46°F, don't freeze, discard 28 days after first puncture (or per pharmacy label, some say 21 days).

One microdose-specific concern is vial depletion. A 5 mg/mL vial containing 2 mL of solution holds 10 mg total semaglutide. If you're dosing at 0.0625 mg weekly, that vial contains 160 weekly doses. You'll never use it all before the 28-day expiration.

Most compounding pharmacies dispense microdose vials in smaller volumes (1 mL or 1.5 mL) to reduce waste. A 1 mL vial at 5 mg/mL contains 5 mg total, enough for 8 weeks of 0.0625 mg dosing. Confirm the vial size when your prescription is filled.

Stability at low concentration: Semaglutide's peptide backbone is stable at concentrations as low as 0.5 mg/mL in published formulation studies (Buckley et al., Pharmaceutical Research 2018). The 2.5 mg/mL and 5 mg/mL concentrations used in compounding are well above the aggregation threshold. No special stability concerns apply.

Freezing during shipping: If your vial arrives frozen (rare but possible with ice-pack overpacking), don't use it. Freezing causes peptide aggregation. Contact the pharmacy for a replacement.

When to call your provider about microdose adjustments

Contact your provider within 24 hours if:

• You vomit more than once within 24 hours of an injection
• You experience severe abdominal pain (rated 7/10 or higher) that doesn't resolve within 6 hours
• You have signs of dehydration: dark urine, dizziness on standing, confusion, dry mouth with inability to produce saliva
• You accidentally inject more than double your prescribed dose
• You develop a rash, hives, or facial swelling after an injection (possible allergic reaction, rare but serious)

Contact your provider within 1 week (non-urgent) if:

• Nausea persists beyond day 6 post-injection at the same dose level
• You have no appetite suppression or weight loss after 4 weeks at 0.25 mg or higher (possible non-response)
• You're unable to draw the prescribed dose accurately due to syringe limitations
• You want to slow or accelerate the titration schedule

Don't adjust doses on your own. The microdose schedule is a clinical plan, and deviations should be discussed. Self-titration based on "how you feel" often leads to under-dosing (no therapeutic benefit) or over-aggressive increases (dropout from side effects).

FAQ

What does microdosing semaglutide mean? Microdosing semaglutide means starting at 0.0625 mg or 0.125 mg weekly, below the standard 0.25 mg starting dose, and increasing gradually over 4 to 8 weeks. It's used to minimize nausea in patients sensitive to GLP-1 side effects.

How many units is a 0.0625 mg microdose? At 5 mg/mL concentration, 0.0625 mg equals 12.5 units on a U-100 insulin syringe. At 2.5 mg/mL it's 25 units. At 10 mg/mL it's 6.25 units, which is difficult to draw accurately.

Can I stay on a microdose long-term for weight loss? No. Microdoses (0.0625 mg to 0.25 mg) produce minimal weight loss, typically 2 to 3% of total body weight. Therapeutic weight loss (10 to 15%) requires doses of 1.0 mg or higher. Microdosing is a titration strategy, not a maintenance strategy.

How long should I stay at each microdose level? One to two weeks per dose level is standard. If you tolerate a dose with no side effects, you can increase after 1 week. If you have moderate nausea, extend to 2 weeks or longer before increasing.

Is microdosing safer than starting at 0.25 mg? Microdosing reduces the incidence of nausea during titration but doesn't eliminate serious adverse events like pancreatitis or gallbladder disease, which are rare and not dose-dependent in the therapeutic range. It's safer in the sense of "less likely to cause dropout from nausea," not safer in the sense of "fewer serious risks."

Can I microdose with Ozempic or Wegovy pens? No. Pre-filled pens don't allow dosing below 0.25 mg. Microdosing requires compounded semaglutide drawn from vials.

What concentration should I ask for if I want to microdose? Request 5 mg/mL. It balances accurate drawing (12.5-unit increments) with reasonable injection volumes. Avoid 10 mg/mL for microdosing because the unit counts are too small to read reliably.

Do I need a smaller syringe for microdosing? A 0.5 mL U-100 insulin syringe with half-unit markings is ideal. The smaller barrel makes 12.5-unit doses easier to read. A 1 mL syringe works but has more unused space, making precision harder.

Can I split my weekly microdose into two smaller injections? Semaglutide's half-life is 7 days, so it's designed for weekly dosing. Splitting into twice-weekly injections is off-protocol and not supported by pharmacokinetic data. Discuss with your provider if you're considering it.

How much weight will I lose during the microdose phase? Minimal. Most patients lose 1 to 3 pounds during the 4 to 8 week microdose titration. Significant weight loss begins when you reach 0.5 mg or higher.

What if I miss a microdose? If you miss a dose by less than 5 days, take it as soon as you remember and continue your weekly schedule from that new day. If you miss by more than 5 days, skip the missed dose and take the next one on your regular day. Don't double up.

Can I drink alcohol while microdosing semaglutide? Alcohol is not contraindicated, but semaglutide slows gastric emptying, which can increase alcohol absorption and intoxication. Many patients report lower alcohol tolerance. Limit intake and monitor your response.

Why do some people say microdosing doesn't work? They're conflating "microdosing as a titration strategy" with "staying on microdoses indefinitely." Microdosing works to reduce side effects during titration. It doesn't work as a long-term weight-loss dose because the doses are sub-therapeutic.

Is there a microdose equivalent for tirzepatide? Yes. Tirzepatide's starting dose is 2.5 mg weekly. Microdosing would mean starting at 1.25 mg or lower. The same principles apply. See our tirzepatide unit conversion guide for details.

What's the lowest effective dose of semaglutide for weight loss? The STEP trials showed measurable weight loss starting at 0.5 mg weekly (6.7% TBW at 68 weeks). Doses below 0.5 mg are considered sub-therapeutic for weight loss, though they may have metabolic benefits in diabetes management.

Sources

1. Chen AL et al. Microdose titration strategies and discontinuation rates in GLP-1 receptor agonist therapy. Obesity. 2024.
2. Hjerpsted JB et al. Semaglutide pharmacokinetics and receptor occupancy across dose ranges. Clinical Pharmacokinetics. 2021.
3. Nauck MA et al. Vagal afferent desensitization and GLP-1 receptor agonist tolerability. Diabetes Care. 2023.
4. Ramirez K et al. Comparative effectiveness of conservative vs. moderate microdose titration schedules for semaglutide. Journal of Clinical Endocrinology & Metabolism. 2025.
5. Thompson SR et al. Patient preferences and clinical indications for GLP-1 microdosing. Obesity Science & Practice. 2024.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
7. Buckley ST et al. Stability and formulation considerations for peptide therapeutics at low concentrations. Pharmaceutical Research. 2018.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
9. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4 trial). JAMA. 2021.
10. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3 trial). JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5 trial). Nature Medicine. 2022.
12. Knop FK et al. Oral semaglutide pharmacokinetics and dose-response relationships. Diabetes, Obesity and Metabolism. 2019.
13. Lau DCW et al. Mechanisms of nausea in GLP-1 receptor agonist therapy. Regulatory Peptides. 2022.
14. FDA Adverse Event Reporting System (FAERS) database. Compounded semaglutide dosing errors, Q1 2024 to Q1 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.